An interventional study of omega-3 fatty acid alpha-linolenic acid (ALA) and Placebo in Attention Deficit Hyperactivity Disorder, sponsored by Hadassah Medical Organization. Completed at 1 site in Israel. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2013-07-30.
Sponsored by Hadassah Medical Organization · Not applicable, Interventional, and Treatment
It is assumed that only 1/5 of children diagnosed with attention-deficit-hyperactivity disorder (ADHD) are treated. New treatment modalities are urgently needed. Omega-3 fatty acids have been used in this setting, yet results are conflicting. The parent omega-3 fatty acid alpha-linolenic acid (ALA) has only been used in one trial. 40 children diagnosed with ADHD will be randomized to consume either ALA or placebo for two months. Baseline and end assessments will include ADHD-related questionnaires and a computerized test. The investigators hypothesize that ALA supplementation will prove beneficial for children with ADHD.
729 studies on the registry are indexed under Hyperkinesis; 25 are open to participants now.
This study's enrollment of 40 is below the median of 80 across 583 interventional studies indexed under Hyperkinesis.
Browse Hyperkinesis studies →Hadassah Medical Organization is the lead sponsor of 659 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This group will receive the ALA supplement
Dietary Supplement: omega-3 fatty acid alpha-linolenic acid (ALA)
This group will receive the placebo supplement
Dietary Supplement: Placebo
3 grams of ALA-containing plant oil
ADHD symptoms
scores of DSM and Conners questionnaires
Time frame: 8 weeks
Computerized test performance
performance in a computerized test of attention
Time frame: 8 weeks
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hadassah Medical Organization